| 1. |
- Chyzhma, Ruslana, et al.
(författare)
-
The study of the nanocrystalline structure of psammoma bodies of serous ovarian carcinoma
- 2022
-
Ingår i: 2022 IEEE 12th international conference nanomaterials. - : IEEE. - 9781665489829 - 9781665489836 ; , s. NRA03-1-NRA03-4
-
Konferensbidrag (refereegranskat)abstract
- Psammoma Bodies (PBs) are concentric calcined structures. The formation of PBs begins during the initial stages of carcinogenesis, which is an important feature for the diagnostics of serous ovarian carcinoma. The aim of our work was to study the nanocrystalline structure of PBs of serous ovarian carcinoma for practical use in diagnostics. According to the size, these structures were divided into 3 groups: large - more than 200μm, medium - 71-199μm, and small - up to 70μm. The structure of PBs was represented by lamellae and interlamellar layers. The mean thickness of the lamellae was 0.65 ± 0.02μm, and the thickness of the inter-lamellar layers was 3.7 ± 0.17μm. A strong correlation between the thickness of the interlamellar layer and the size of PBs was found for all groups of calcifications. It has been found that PBs consisted of hydroxyapatite and contained proteins. Therefore, based on the nanocrystalline structure and morphometric characteristics of PBs, this pattern can be used in practice for the early diagnosis of serous ovarian cancer.
|
|
| 2. |
- Grüning, Björn, et al.
(författare)
-
Bioconda: A sustainable and comprehensive software distribution for the life sciences
- 2017
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- We present Bioconda (https://bioconda.github.io), a distribution of bioinformatics software for the lightweight, multi-platform and language-agnostic package manager Conda. Currently, Bioconda offers a collection of over 3000 software packages, which is continuously maintained, updated, and extended by a growing global community of more than 200 contributors. Bioconda improves analysis reproducibility by allowing users to define isolated environments with defined software versions, all of which are easily installed and managed without administrative privileges.
|
|
| 3. |
- Kolomiiets, Olena, et al.
(författare)
-
The expression of prolactin receptors in benign breast tumors is not associated with serum prolactin level
- 2021
-
Ingår i: Journal of Clinical Medicine. - : MDPI. - 2077-0383. ; 10:24
-
Tidskriftsartikel (refereegranskat)abstract
- The role of prolactin (PRL) and its receptors in the initiation and development of benign breast tumors (BBT) has not been sufficiently studied. An imbalance in the system of hormone homeostasis is crucial in the development of BBT. In particular, an association between elevated prolactin levels and the development of BBT has been reported. Our study showed no significant differences between PRL receptor (PRL-R) expression in BBT tissue under normal and elevated serum PRL levels. There was also no significant correlation between age, PRL-R expression in BBT tissue, intact tissue, and PRL level in the serum. There was a strong significant correlation (p < 0.01; r = 0.92) between PRL-R expression in BBT samples and intact breast tissue, which did not depend on the serum PRL level. There was also no significant difference in the expression of the proliferative marker Ki-67 in BBT tissues from women with normal and elevated levels of serum PRL (p > 0.05). No signs of PRL and its receptors were detected in the BBT cystic fluid women with elevated serum PRL levels. In summary, our prospective study showed that the expression of PRL-R in the tissue of BBT and physiological breast tissue does not depend on the level of serum PRL.
|
|
